Bulevirtide and tenofovir combination therapy for hepatitis D virus infection: longer treatment and more diverse trial populations are needed
- PMID: 36113539
- DOI: 10.1016/S1473-3099(22)00412-1
Bulevirtide and tenofovir combination therapy for hepatitis D virus infection: longer treatment and more diverse trial populations are needed
Conflict of interest statement
MHN reports research support from Pfizer, Enanta, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, BK Kee Foundation, and CurveBio, and consulted or was on the advisory board for Intercept, Exact Science, Gilead, GSK, Eli Lilly, and Laboratory of Advanced Medicine. TI reports speaker's fees from Chugai Pharmaceutical.
Comment on
-
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
